151 related articles for article (PubMed ID: 25064355)
1. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Saito M; Ishigame T; Tsuta K; Kumamoto K; Imai T; Kohno T
Carcinogenesis; 2014 Nov; 35(11):2452-6. PubMed ID: 25064355
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
3. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
4. KIF5B-RET fusions in lung adenocarcinoma.
Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
[TBL] [Abstract][Full Text] [Related]
5. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Lee MS; Kim RN; I H; Oh DY; Song JY; Noh KW; Kim YJ; Yang JW; Lira ME; Lee CH; Lee MK; Kim YD; Mao M; Han J; Kim J; Choi YL
Oncotarget; 2016 Jun; 7(24):36101-36114. PubMed ID: 27150058
[TBL] [Abstract][Full Text] [Related]
7. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
[TBL] [Abstract][Full Text] [Related]
8. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
10. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
11. RET fusion gene: translation to personalized lung cancer therapy.
Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer.
Gow CH; Liu YN; Li HY; Hsieh MS; Chang SH; Luo SC; Tsai TH; Chen PL; Tsai MF; Shih JY
Neoplasia; 2018 Aug; 20(8):838-847. PubMed ID: 30015159
[TBL] [Abstract][Full Text] [Related]
13. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
14. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS
Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472
[TBL] [Abstract][Full Text] [Related]
15. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
16. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
18. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
19. KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.
Das TK; Cagan RL
Cell Rep; 2017 Sep; 20(10):2368-2383. PubMed ID: 28877471
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
Song M; Kim SH; Yoon SK
Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
